MMV371

Translational

-

Preclinical

Janssen

Asexual blood stages

Chemoprevention

Product vision	Prophylaxis: long-acting injectable
MOA	Prodrug; active moiety is atovaquone (selective inhibitor of cytochrome bc1 complex)
Key features	Prodrug of well-tolerated, marketed prophylactic drug (atovaquone) Targets actively replicating parasites in the liver, bloodstream, and vector stages of infection Potential partner for MMV055 in a long-acting injectable product
Challenges	Development of a combination product
Status	Preclinical development - Good Laboratory Practice intra-muscular safety studies complete CMC - Good Manufacturing Practice drug product manufacture ongoing
Next milestone	Start of first-in-human phase I in Q3 2023
Previously	Discovery partnership between MMV and Calibr Name: mCBE161
Project Director	Dr Andrew Slade